Waters Corporation

Waters Corporation reported second-quarter 2026 adjusted earnings of $3.05 per share, up 3.4% year over year and surpassing the Zacks Consensus Estimate by 1.33%. Revenues of $1.645 billion surged 113.4% from the year-ago quarter, topping the consensus mark by 1.25%, with organic revenues rising 9% in constant currency. The acquired Biosciences and Diagnostic Solutions businesses generated $817 million, exceeding guidance by $15 million. Reflecting broad-based strength, Waters raised its 2026 organic constant-currency revenue growth guidance to 7%-9% and lifted adjusted earnings guidance to $14.45-$14.65 per share. The company also expects total reported revenues between $6.415 billion and $6.476 billion for the year, with acquired businesses contributing approximately $3.045 billion. Management highlighted continued execution gains, including remediation of roughly 700 U.S. Diagnostic Solutions reagent rental contracts and plans to launch the FACSDiscover A7 Cell Analyzer on Sept. 15.

Waters Corporation, a maker of products used in drug discovery and development, shows a positive Earnings ESP of +0.45% ahead of its next earnings report expected on August 4, 2026. The company has an established record of topping earnings estimates, with an average surprise of 8.77% over the past two quarters. For the most recent quarter, Waters reported earnings of $2.70 per share versus a consensus estimate of $2.31, a surprise of 16.88%, while the previous quarter saw earnings of $4.53 per share against a $4.50 estimate. The stock holds a Zacks Rank #3 (Hold), and the combination of a positive Earnings ESP and a Zacks Rank #3 or better has historically produced a positive surprise nearly 70% of the time.

Waters Corporation delivered the strongest first-quarter performance among the ten research tools and consumables stocks tracked, with revenues of $1.27 billion, up 91.5% year on year and beating analysts' estimates by 4.5%. The company also posted the biggest analyst estimate beat, highest guidance raise, and fastest revenue growth among its peers. Avantor reported revenues of $1.58 billion, flat year on year but exceeding expectations by 2.7%, while Revvity's revenues of $686.9 million, up 9.3% year on year, fell short of estimates by 2.6% and came with full-year guidance that missed expectations. Sotera Health Company posted revenues of $280 million, up 10% year on year and topping estimates by 3.6%, and Bio-Techne reported revenues of $311.4 million, down 1.5% year on year and missing estimates by 1.6%. Overall, the group's revenues beat consensus estimates by 1.3%, and next-quarter revenue guidance was 2% above expectations, with share prices up 22.5% on average since the latest earnings results.

The ten research tools and consumables stocks tracked reported mixed first-quarter results, with aggregate revenues beating analysts' consensus estimates by 1.3% and next-quarter revenue guidance coming in 2% above expectations. Mettler-Toledo posted revenues of 947.1 million dollars, up 7.2% year on year and slightly ahead of estimates, though the quarter was mixed overall. Waters Corporation stood out with revenues of 1.27 billion dollars, a 91.5% year-on-year surge that exceeded estimates by 4.5%, and it delivered the biggest analyst estimate beat, highest guidance raise, and fastest revenue growth among its peers. Revvity's revenues of 686.9 million dollars, up 9.3% year on year, missed estimates by 2.6% and it issued full-year guidance below expectations, marking the weakest performance against estimates in the group. Sotera Health Company reported revenues of 280 million dollars, up 10% year on year and beating estimates by 3.6%, while Bruker's revenues of 823.4 million dollars, up 2.7% year on year, topped estimates by 3.4%. Share prices of the group have risen 20.8% on average since the latest earnings results.

IMU Biosciences has selected Waters Corporation as a strategic partner to accelerate its AI-driven High Definition Immunology platform. The collaboration will combine Waters Biosciences' flow cytometry and single-cell technologies, including BD FACSDiscover Cell Analyzers and BD Rhapsody Instruments, with IMU's proprietary machine learning analytics that can measure over 100 million data points from a single blood sample. IMU is building what it calls the world's largest immune dataset, and the partnership supports its expansion through large-scale studies aimed at establishing a universal standard for immune profiling. The companies intend to pursue additional translational research for novel biomarker discovery and presented system-level immune profiling data at the CYTO 2026 annual meeting.